Therapeutic Effect of Recombinant Human Endostatin Combined with SOX Regimen on Patients with Advanced Colorectal Cancer and its Changes of Serum ICAM-1 and VCAM-1
YU Deng-feng,ZHANG Wen-jun,ZHANG Fu-jie
Department of Anorectal Surgery, Dalian University affiliated Xinhua Hospital, Dalian 116021, China
Abstract:
Objective To study the therapeutic effect of recombinant human endostatin combined with SOX regimen on patients with advanced colorectal cancer and its changes of serum ICAM-1 and VCAM-1. Methods A total of 127 patients with late colorectal cancer between January 2010 and January 2015 were randomly assigned to treatment group (63) and control group (64). The treatment group was treated with recombinant human endostatin combined with SOX regimen, and the control group was treated with SOX alone. The short-term and long-term efficacy, quality of life and adverse reactions of the two groups and the changes of serum ICAM-1 and VCAM-1 before and after treatment were compared. Results The total effective rate (ORR) of the treatment group and the control group were 60.32% (38/63) and 42.19% (27/64), respectively resulting statistically significant (χ2 =4.177, P=0.044). The disease control rate (DCR) of the two groups was 82.54% (52/63) and 67.19% (43/64) (χ2 =3.970, P=0.046). The 3-year overall survival rate (log-rank, P=0.67) was not statistically significant between the two groups. The quality of life were similar between two groups. Additionally, there was no statistically significant difference between the two groups in the incidence of adverse events. The levels of ICAM-1 and VCAM-1 in the two groups were lower than those before treatment (P<0.05), and the levels of ICAM-1 and VCAM-1 in the treatment group were lower than those in the control group (P<0.05). Conclusion The use of recombinant human endostatin combined with SOX could decline the expression of serum ICAM-1 and VCAM-1, which could achieve a better short-term outcome with similar incidence of adverse reactions.
